Authors:
MAYALL TP
SHERIDAN PL
MONTMINY MR
JONES KA
Citation: Tp. Mayall et al., DISTINCT ROLES FOR P-CREB AND LEF-1 IN TCR-ALPHA ENHANCER ASSEMBLY AND ACTIVATION ON CHROMATIN TEMPLATES IN-VITRO, Genes & development, 11(7), 1997, pp. 887-899
Authors:
GREENGARD JS
BODNER M
MCCORMACK J
EDWARDS WR
SENSINTAFFAR JL
SHERIDAN PL
PHUONG T
MITTELSTAEDT D
BRUMM D
NICHOLS TC
READ M
BRINKHOUS KM
JOLLY DJ
CHANG SMW
Citation: Js. Greengard et al., SYSTEMIC EXPRESSION OF HUMAN FACTOR-VIII FROM PERIPHERAL RETROVIRAL GENE DELIVERY IN RABBITS AND DOGS, Blood, 90(10), 1997, pp. 1054-1054
Authors:
PAZIN MJ
SHERIDAN PL
CANNON K
CAO ZD
KECK JG
KADONAGA JT
JONES KA
Citation: Mj. Pazin et al., NF-KAPPA-B-MEDIATED CHROMATIN RECONFIGURATION AND TRANSCRIPTIONAL ACTIVATION OF THE HIV-1 ENHANCER IN-VITRO, Genes & development, 10(1), 1996, pp. 37-49
Authors:
SHERIDAN PL
SHELINE CT
CANNON K
VOZ ML
PAZIN MJ
KADONAGA JT
JONES KA
Citation: Pl. Sheridan et al., ACTIVATION OF THE HIV-1 ENHANCER BY THE LEE-1 HMG PROTEIN ON NUCLEOSOME-ASSEMBLED DNA IN-VITRO, Genes & development, 9(17), 1995, pp. 2090-2104
Citation: Y. Lin et al., THE HIP116 SNF2 SW12-RELATED TRANSCRIPTION FACTOR GENE (SNF2L3) IS LOCATED ON HUMAN-CHROMOSOME 3Q25.1-Q26.1/, Genomics, 27(2), 1995, pp. 381-382
Citation: Pl. Sheridan et al., DEVELOPMENT OF A FLOW MICROCALORIMETRY METHOD FOR THE ASSESSMENT OF SURFACE-PROPERTIES OF POWDERS, Pharmaceutical research, 12(7), 1995, pp. 1025-1030
Citation: Pl. Sheridan et al., THE USE OF MOLECULAR-ORBITAL INDEXES TO PREDICT THE SURFACE-PROPERTIES OF PHARMACEUTICAL POWDERS, International journal of pharmaceutics, 125(1), 1995, pp. 141-149
Citation: Pl. Sheridan et al., CLONING OF AN SNF2 SWI2-RELATED PROTEIN THAT BINDS SPECIFICALLY TO THE SPH MOTIFS OF THE SV40 ENHANCER AND TO THE HIV-1 PROMOTER/, The Journal of biological chemistry, 270(9), 1995, pp. 4575-4587
Citation: Pl. Sheridan et al., THE EXTENT OF ERRORS ASSOCIATED WITH CONTACT ANGLES .2. FACTORS AFFECTING DATA OBTAINED USING A WILHELMY PLATE TECHNIQUE FOR POWDERS, International journal of pharmaceutics, 109(2), 1994, pp. 155-171